Leerink Partnrs Issues Pessimistic Estimate for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities researchers at Leerink Partnrs reduced their Q1 2026 earnings estimates for Agilent Technologies in a research report issued on Monday, November 24th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $1.37 for the quarter, down from their prior estimate of $1.38. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q2 2026 earnings at $1.43 EPS, Q3 2026 earnings at $1.53 EPS, Q4 2026 earnings at $1.60 EPS, FY2026 earnings at $5.92 EPS and FY2027 earnings at $6.46 EPS.

A number of other analysts have also weighed in on A. Wall Street Zen upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Evercore ISI boosted their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a report on Tuesday, October 7th. UBS Group upped their price objective on Agilent Technologies from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Tuesday. Rothschild & Co Redburn assumed coverage on Agilent Technologies in a report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 target price for the company. Finally, Bank of America upped their price target on Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $161.08.

Agilent Technologies Trading Down 1.7%

NYSE A opened at $154.52 on Wednesday. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $160.27. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The stock’s fifty day moving average price is $141.89 and its 200-day moving average price is $126.43. The stock has a market cap of $43.81 billion, a P/E ratio of 36.27, a P/E/G ratio of 4.67 and a beta of 1.29.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.01. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm had revenue of $1.86 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same period in the previous year, the firm posted $1.46 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 6th will be paid a dividend of $0.255 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, January 6th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.25. Agilent Technologies’s dividend payout ratio (DPR) is 22.32%.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 12,490 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the transaction, the chief executive officer directly owned 33,448 shares in the company, valued at $5,017,200. This represents a 27.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors have recently bought and sold shares of A. Resona Asset Management Co. Ltd. raised its holdings in shares of Agilent Technologies by 6.2% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock worth $11,631,000 after acquiring an additional 5,767 shares in the last quarter. TrueMark Investments LLC bought a new stake in Agilent Technologies in the second quarter worth $1,999,000. Fenimore Asset Management Inc raised its stake in Agilent Technologies by 2.7% during the second quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after purchasing an additional 4,823 shares in the last quarter. Nuance Investments LLC lifted its position in Agilent Technologies by 13.5% during the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock valued at $9,523,000 after purchasing an additional 9,628 shares during the last quarter. Finally, Asset Management One Co. Ltd. grew its stake in shares of Agilent Technologies by 3.4% in the 2nd quarter. Asset Management One Co. Ltd. now owns 124,577 shares of the medical research company’s stock worth $14,701,000 after buying an additional 4,152 shares in the last quarter. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.